search
Back to results

Physiological Study of Minimally Invasive ECCO2R in Exacerbations of COPD Requiring Invasive Mechanical Ventilation (EPHEBE)

Primary Purpose

Chronic Obstructive Pulmonary Disease

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
extracorporeal CO2 removal (Hemolung device)
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring extracorporeal CO2 removal

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • clinical exacerbation of a known or suspected COPD
  • intubation and invasive mechanical ventilation since less than 72 hrs.
  • ACV or CV mode (VT 8 ml/kg, RR 12/min., PEEP : 0 cmH20)
  • pH < 7.30 and PaCO2 > 55 mm Hg and PEEPi (end-expiratory occlusion) > 5 cmH20
  • written inform consent (patient, patient's legal surrogate)
  • affiliation to a social security regime

Exclusion Criteria:

  • Body Mass Index (BMI) > 35 kg/m2
  • PaO2/FiO2 < 200 mm Hg
  • history of hemorrhagic stroke
  • heparin-induced thrombocytopenia
  • Severe thrombopenia type II history

Sites / Locations

  • CHU d'Angers
  • Hopital de Bicetre, Hopitaux universitaires Paris Sud
  • Hopital Europeen Georges Pompidou

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

extracorporeal CO2 removal

Arm Description

extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device

Outcomes

Primary Outcome Measures

intrinsic PEEP (PEEPi)
PEEPi at baseline and after ECCO2R by the Hemolung® device and adjustment of ventilator settings, expressed in cmH20

Secondary Outcome Measures

Functional Residual capacity (FRC)
FRC using the nitrogen washout method, expressed in mL
PaO2
PaO2 expressed in mmHg
PaCO2
PaCO2 expressed in mmHg
Arterial O2 saturation
Arterial O2 saturation expressed in %
pH
pH expressed in absolute value
amount of sedative drugs
amount of sedative drugs (per day and cumulative)
length of intubation
length of intubation (days)
length of ICU-stay
length of ICU-stay (days)
length of hospital stay
length of hospital stay (days)
ICU mortality
Number of in ICU-deceased participants (expressed in absolute number and %)
catheter related complications
catheter related complications (thrombosis, bleeding, pneumothorax, infection) expressed in total number of complications, in average number of complications per participant and in number of patients with complications
Hemolung related complications
Hemolung related complications (thrombosis, bleeding) expressed in total number of complications, in average number of complications per participant and in number of patients with complications
non catheter-related bleedings
non catheter-related bleedings expressed in total number of bleedings, in average number of bleedings per participant and in number of patients with bleedings
work of breathing per Liter
work of breathing with and without ECCO2R, expressed in Joules per Liter of ventilation
work of breathing per minute
work of breathing with and without ECCO2R, expressed in Joules per minute
work of breathing per breath
work of breathing with and without ECCO2R, expressed in Joules per breath
Occlusion pressure in 100msec (P0.1)
Occlusion pressure in 100msec in parallel to work breathing measurements with and without ECCO2, expressed in cmH2O

Full Information

First Posted
August 31, 2015
Last Updated
February 26, 2018
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Alung Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT02586948
Brief Title
Physiological Study of Minimally Invasive ECCO2R in Exacerbations of COPD Requiring Invasive Mechanical Ventilation
Acronym
EPHEBE
Official Title
Physiological Study of Minimally Invasive Extracorporeal CO2 Removal in Exacerbations of COPD Requiring Invasive Mechanical Ventilation
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
July 2016 (undefined)
Primary Completion Date
January 14, 2018 (Actual)
Study Completion Date
February 12, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Alung Technologies

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Morbidity and mortality in COPD result largely of acute exacerbations.The optimization of the respiratory management represents a fundamental challenge for improving prognosis and reducing mortality. While the hospital mortality of patients treated with NIV has decreased over years, and is currently less than 10 %, mortality in patients treated with invasive ventilation remains higher than 25%. To improve the prognosis of patients with acute exacerbation of COPD requiring invasive mechanical ventilation is therefore a major challenge in terms of morbidity and mortality. Among the means available to achieve this goal, minimally invasive extracorporeal CO2 removal (ECCO2R) seems to be a very promising approach. The investigators hypothesize that the addition of minimally invasive ECCO2R is likely to limit dynamic hyperinflation in COPD patients requiring invasive mechanical ventilation for an acute exacerbation, while improving gas exchange.
Detailed Description
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the U.S. and is expected to become the third leading cause of death in 2020. Morbidity and mortality in COPD result largely of acute exacerbations, which are responsible for 1.5 million ED visits and 750,000 hospitalizations per year in the U.S. The optimization of the respiratory management of acute exacerbations represents a fundamental challenge for improving prognosis and reducing mortality. The value of non-invasive ventilation (NIV) for severe acute exacerbations of COPD was formally demonstrated by randomized clinical trials. In the setting of severe COPD exacerbations, NIV is actually very largely employed, largely ahead from invasive mechanical ventilation. While the hospital mortality of patients treated with NIV has decreased over years, and is currently less than 10 %, mortality in patients treated with invasive ventilation remains as high than 25%. Mortality in patients treated with invasive ventilation after failure of NIV seems to be growing and is actually close to 30%. To improve the prognosis of patients with acute exacerbation of COPD requiring invasive mechanical ventilation is therefore a major challenge in terms of morbidity and mortality. Among the means available to achieve this goal, minimally invasive extracorporeal CO2 removal (ECCO2R) seems to be a very promising approach. The investigators hypothesize that the addition of minimally invasive ECCO2R is likely to limit dynamic hyperinflation in COPD patients requiring invasive ventilation for an acute exacerbation, while improving gas exchange. If confirmed, it could imply a more rapid weaning from invasive ventilation in relation to: less hemodynamic consequences of positive pressure ventilation reduced risk of baro-volo trauma of the lung parenchyma reduction in the use of sedative drugs a chest configuration minimizing diaphragmatic flattening, therefore favoring the generation of higher trans-diaphragmatic pressures a decrease in the work of breathing (WOB), in connection with the previous point and with a decrease in alveolar ventilation required for pulmonary CO2 elimination during the ECCO2R treatment All of these elements are clinically relevant, as a reduction in the duration of invasive ventilation is associated in the literature with a decrease in the incidence of pneumonia associated with mechanical ventilation, as well as with a decrease in the duration of ICU-stay.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease
Keywords
extracorporeal CO2 removal

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
extracorporeal CO2 removal
Arm Type
Experimental
Arm Description
extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
Intervention Type
Device
Intervention Name(s)
extracorporeal CO2 removal (Hemolung device)
Other Intervention Name(s)
ECCO2R
Intervention Description
ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
Primary Outcome Measure Information:
Title
intrinsic PEEP (PEEPi)
Description
PEEPi at baseline and after ECCO2R by the Hemolung® device and adjustment of ventilator settings, expressed in cmH20
Time Frame
12 hours (between measurements at baseline and under ECCO2R)
Secondary Outcome Measure Information:
Title
Functional Residual capacity (FRC)
Description
FRC using the nitrogen washout method, expressed in mL
Time Frame
12 hours (between measurements at baseline and under ECCO2R)
Title
PaO2
Description
PaO2 expressed in mmHg
Time Frame
12 hours (between measurements at baseline and under ECCO2R)
Title
PaCO2
Description
PaCO2 expressed in mmHg
Time Frame
12 hours (between measurements at baseline and under ECCO2R)
Title
Arterial O2 saturation
Description
Arterial O2 saturation expressed in %
Time Frame
12 hours (between measurements at baseline and under ECCO2R)
Title
pH
Description
pH expressed in absolute value
Time Frame
12 hours (between measurements at baseline and under ECCO2R)
Title
amount of sedative drugs
Description
amount of sedative drugs (per day and cumulative)
Time Frame
Average time period of 6 days
Title
length of intubation
Description
length of intubation (days)
Time Frame
Average time period of 7 days, up to 28 days
Title
length of ICU-stay
Description
length of ICU-stay (days)
Time Frame
Average time period of 8 days, up to 28 days
Title
length of hospital stay
Description
length of hospital stay (days)
Time Frame
Average time period of 9 days, up to 28 days
Title
ICU mortality
Description
Number of in ICU-deceased participants (expressed in absolute number and %)
Time Frame
Average time period of 9 days, up to 28 days
Title
catheter related complications
Description
catheter related complications (thrombosis, bleeding, pneumothorax, infection) expressed in total number of complications, in average number of complications per participant and in number of patients with complications
Time Frame
Average time period of 9 days
Title
Hemolung related complications
Description
Hemolung related complications (thrombosis, bleeding) expressed in total number of complications, in average number of complications per participant and in number of patients with complications
Time Frame
Average time period of 9 days
Title
non catheter-related bleedings
Description
non catheter-related bleedings expressed in total number of bleedings, in average number of bleedings per participant and in number of patients with bleedings
Time Frame
Average time period of 9 days
Title
work of breathing per Liter
Description
work of breathing with and without ECCO2R, expressed in Joules per Liter of ventilation
Time Frame
Average time period of 7 days
Title
work of breathing per minute
Description
work of breathing with and without ECCO2R, expressed in Joules per minute
Time Frame
Average time period of 7 days
Title
work of breathing per breath
Description
work of breathing with and without ECCO2R, expressed in Joules per breath
Time Frame
Average time period of 7 days
Title
Occlusion pressure in 100msec (P0.1)
Description
Occlusion pressure in 100msec in parallel to work breathing measurements with and without ECCO2, expressed in cmH2O
Time Frame
Average time period of 7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: clinical exacerbation of a known or suspected COPD intubation and invasive mechanical ventilation since less than 72 hrs. ACV or CV mode (VT 8 ml/kg, RR 12/min., PEEP : 0 cmH20) pH < 7.30 and PaCO2 > 55 mm Hg and PEEPi (end-expiratory occlusion) > 5 cmH20 written inform consent (patient, patient's legal surrogate) affiliation to a social security regime Exclusion Criteria: Body Mass Index (BMI) > 35 kg/m2 PaO2/FiO2 < 200 mm Hg history of hemorrhagic stroke heparin-induced thrombocytopenia Severe thrombopenia type II history
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Luc Diehl
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU d'Angers
City
Angers
ZIP/Postal Code
49933
Country
France
Facility Name
Hopital de Bicetre, Hopitaux universitaires Paris Sud
City
Kremlin Bicetre
ZIP/Postal Code
94275
Country
France
Facility Name
Hopital Europeen Georges Pompidou
City
Paris
ZIP/Postal Code
75015
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
32990836
Citation
Diehl JL, Piquilloud L, Vimpere D, Aissaoui N, Guerot E, Augy JL, Pierrot M, Hourton D, Arnoux A, Richard C, Mancebo J, Mercat A. Physiological effects of adding ECCO2R to invasive mechanical ventilation for COPD exacerbations. Ann Intensive Care. 2020 Sep 29;10(1):126. doi: 10.1186/s13613-020-00743-y.
Results Reference
derived

Learn more about this trial

Physiological Study of Minimally Invasive ECCO2R in Exacerbations of COPD Requiring Invasive Mechanical Ventilation

We'll reach out to this number within 24 hrs